FDA Approved: RISPERIDONE — Supplemental Application (Par Health USA, LLC)

View source ↗

Summary

The FDA approved a supplemental application for risperidone submitted by Par Health USA, LLC (ANDA 077494).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Bipolar Disorder
• Irritability Associated with Autistic Disorder
• Schizophrenia

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

SUPPL AP for RISPERIDONE (RISPERIDONE)